+ 1 888 391 5441

China Blood Product Industry Report, 2019-2025

Table of Contents

1. Overview of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Development of China Blood Product Industry
2.1 Related Policies
2.2 Status Quo
2.3 Market Structure
2.4 Market Supply and Demand
2.4.1 Supply
2.4.2 Demand
2.5 Market Size
2.6 Competition Pattern

3. Market Segments of China Blood Product Industry
3.1 Human Albumin
3.1.1 Development Status
3.1.2 Bid Price
3.1.3 Market Structure
3.1.4 Competition Pattern
3.1.5 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Development Status
3.2.2 Bid Price
3.2.3 Competition Pattern
3.2.4 Prospects
3.3 Coagulation Factor VIII
3.3.1 Development Status
3.3.2 Bid Price
3.3.3 Competition Pattern
3.3.4 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Development Status
3.4.2 Bid Price
3.4.3 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Development Status
3.5.2 Bid Price
3.5.3 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Development Status
3.6.2 Bid Price
3.6.3 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Development Status
3.7.2 Bid Price
3.7.3 Competition Pattern
3.8 Human Rabies Immunoglobulin
3.8.1 Development Status
3.8.2 Bid Price
3.8.3 Competition Pattern

4. Major Enterprises
4.1 China Biologic Products (CBPO)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Strucuture
4.1.4 Gross Margin
4.1.5 R&D Investment
4.1.6 Blood Products Business
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Shandong Taibang Biological Products Co., Ltd.
4.1.9 Xi'an Huitian Blood Products Co., Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Strucuture
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Blood Products Business
4.2.7 Development Strategy
4.3 Shanghai RAAS Blood Products
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Strucuture
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Blood Products Business
4.3.7 Development Strategy
4.4 Beijing Tiantan Biological Products
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Strucuture
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Blood Products Business
4.4.7 Chengdu Rongsheng
4.5 Zhenxing Biopharmaceutical & Chemical
4.5.1 Profile
4.5.2 Operation
4.5.3 Gross Margin
4.5.4 R&D Investment
4.5.5 Blood Products Business
4.5.6 Development Strategy
4.6 Jiangxi Boya Bio-Pharmaceutical
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Blood Products Business
4.6.7 Development Strategy
4.7 Weiguang Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Strucuture
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Blood Products Business
4.7.7 Development Strategy
4.8 Beijing Bohui Innovation Technology
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Strucuture
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Blood Products Business
4.8.7 Development Strategy
4.9 Wuhan ZhongyuanRuide Biological Products
4.9.1 Profile
4.9.2 Operation
4.9.3 Blood Products Business
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.8.1 Profile
4.10.2 Blood Products Business
4.11 Shanxi Kangbao Biological Product
4.11.1 Profile
4.11.2 Blood Products Business
4.12 Green Cross China
4.12.1 Profile
4.12.2 Blood Products Business
4.13 Nanyue Biopharming Corporation Ltd.
4.13.1 Profile
4.13.2 Blood Products Business

5. Summary and Forecast
5.1 Summary
5.2 Development Trend
5.2.1 The Industry Continues to Boom
5.2.2 Industry Integration Speeds Up, Concentration Rises Further
5.2.3 Plasma Collection Volume and Number of Plasma Stations Determine the Status in the Industry
5.2.4 Plasma Volume Increases Progressively
5.2.5 Enterprises Make More Input in R&D of New Products to Sharpen Competitiveness
5.2.6 Comprehensive Utilization of Blood Plasma Gets a Further Rise
5.2.7 Downstream Demand Stimulates the Development of the Industry
5.2.8 Healthcare System Reform Deepens, Gradual Perfection of Medical Insurance System Favors the Development of the Industry

List of Charts

Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison of Recombinant Blood Products in China and Overseas
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs & Expenses
Production & Sales Cycle of Blood Products
Main Policies on China Blood Product Industry, 1989-2017
Development History of China Blood Product Industry
Comparison between China and the United States in Per Capita Consumption of Main Blood Products
Lot Release Volume of Major Blood Products in China, 2014-2018
Blood Product Structure in China (by Lot Release Volume), 2014-2018
Plasma Collection Policies in China vs. USA and European Countries
Per Capita Frequency of Plasma Donation and Plasma Collection Volume in China vs. Euro-America
Number of Plasma Collection Stations and YoY Growth Rate in China, 2008-2018
Plasma Station Approval of Major Blood Product Enterprises in China, 2014-2018
Plasma Collection Volume and YoY Growth Rate in China, 2008-2018
Comparison of Blood Products Listed in National Medical Insurance Catalogue: 2017vs2009
Plasma Supply and Demand in China, 2015-2025E
Comparison of Cap-lift Prices and Original Highest Retail Prices of Blood Products
Market Size of China Blood Product Industry, 2010-2018
Number of Plasma Stations and Plasma Volume of Major Blood Product Enterprises in China, As of Jan. 2019
Main Products of Major Blood Product Manufacturing Enterprises in China
Revenue of Major Blood Product Enterprises in China, 2013-2018
Net Income of Major Blood Product Enterprises in China, 2013-2018
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2018
Market Share of China Blood Product Industry (by Enterprise), 2017
Market Share of China Blood Product Industry (by Enterprise), 2018
Lot Release Volume and YoY Growth Rate of Human Albumin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2018Q4
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2018
Market Share of Human Albumin in China (by Lot Release Volume), 2017
Market Share of Human Albumin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Immunoglobulin for Intravenous Injection in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2018Q4  
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2018
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume of Blood Coagulation Factor VIII in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2018Q4       
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2017
Market Share of Blood Coagulation Factor VIII in China (by Lot Release Volume), 2018
Comparison between China and the United States in Per Capita Consumption of Coagulation Factor VIII
Coagulation Factor VIII R&D Progress of Major Blood Product Enterprises in China     
Lot Release Volume of Hepatitis B Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Hepatitis B Immunoglobulin, 2018Q4
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Hepatitis B Immunoglobulin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin, 2018Q4  
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Human Immunoglobulin in China (by Lot Release Volume), 2018
Lot Release Volume of Human Prothrombin Complex in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Prothrombin Complex, 2018Q4
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2017
Market Share of Human Prothrombin Complex in China (by Lot Release Volume), 2018
Lot Release Volume of Tetanus Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Tetanus Immunoglobulin, 2018Q4
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Tetanus Immunoglobulin in China (by Lot Release Volume), 2018
Cases, Deaths and Mortality of Rabies in China, 2013-2018
Lot Release Volume of Human Rabies Immunoglobulin in China, 2010-2018
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Rabies Immunoglobulin, 2018Q4      
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2017
Market Share of Human Rabies Immunoglobulin in China (by Lot Release Volume), 2018
Product Line of CBPO
Equity Structure of China Biologic Products Holdings
Revenue and Operating Income of CBPO, 2012-2018
Revenue Breakdown of CBPO (by Product), 2012-2018
Revenue Structure of CBPO (by Product), 2012-2018
Gross Margin of CBPO, 2012-2018
R&D Costs and % of Total Revenue of CBPO, 2012-2018
CBPO’s Products under Research and R&D Process by the end of 2017
Lot Release Volume of Blood Products of CBPO, 2016-2018
Main Plasma Collection Stations of Guizhou Taibang Biological Products as of Jan. 2019
Lot Release Volume of Blood Products of Guizhou Taibang Biological Products, 2016-2018
Ownership Structure of Shandong Taibang Biological Products
Main Plasma Collection Stations of Shandong Taibang Biological Products as of Jan. 2019
Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2016-2018
Ownership Structure of Xi'an Huitian Blood Products
Main Plasma Collection Stations of Xi'an Huitian Blood Products as of 2019
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2017-2018
Revenue and Net Income of Hualan Biological Engineering, 2013-2018
Revenue Breakdown of Hualan Biological Engineering (by Product), 2013-2018
Revenue Structure of Hualan Biological Engineering (by Product), 2013-2018
Gross Margin of Blood Products of Hualan Biological Engineering (by Product), 2013-2018
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018
Category and Specification of Blood Products of Hualan Biological Engineering
Revenue of Blood Products of Hualan Biological Engineering, 2013-2018
Lot Release Volume of Blood Products of Hualan Biological Engineering, 2015-2018
Revenue and Net Income of Shanghai RAAS Blood Products, 2013-2018
Revenue Breakdown of Shanghai RAAS Blood Products (by Product), 2013-2018
Revenue Structure of Shanghai RAAS Blood Products (by Product), 2013-2018
Revenue Breakdown of Shanghai RAAS Blood Products (by Region), 2013-2018
Revenue Structure of Shanghai RAAS Blood Products (by Region), 2013-2018
Gross Margin of Shanghai RAAS Blood Products (by Product), 2013-2018
R&D Costs of Shanghai RAAS Blood Products, 2015-2018
Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
Revenue and Net Income of Tiantan Biological Products, 2013-2018
Revenue Breakdown of TIANTANBIO (by Product), 2013-2017
Revenue Structure of TIANTANBIO (by Product), 2013-2017
Gross Margin of TIANTANBIO (by Product), 2013-2017
R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2018
R&D Input of Major Projects of TIANTANBIO, 2017
Progress of Major R&D Projects of TIANTANBIO, by the End of 2017
TIANTANBIO’s Major Blood Products Subsidiaries and Stake
Production and Sales of Main Blood Products of TIANTANBIO, 2017
Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2018
Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2018
Revenue and Net Income of Zhenxing Biopharmaceutical & Chemical, 2013-2018
Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2013-2018
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical & Chemical, 2013-2018
Revenue and Net Income of Shuanglin Bio-Pharmacy, 2014-2018
Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
Production, Inventory and Sales of Main Blood Products of Zhenxing Biopharmaceutical & Chemical, 2013-2017
Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2018
Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2017
Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2013-2017
Gross Margin of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
R&D Costs of Jiangxi Boya Bio-Pharmaceutical, 2013-2018
Production and Sales of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2016-2017
Lot Release Volume of Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
Revenue and Net Income of Shenzhen Weiguang Biological Products, 2014-2018
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2014-2018
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2014-2018
Gross Margin of Shenzhen Weiguang Biological Products, 2014-2018
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2014-2018
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2014-2018
Progress of Fundraising Projects of Shenzhen Weiguang Biological Products, as of 2018H1
Plasma Collection Volume of Shenzhen Weiguang Biological Products, 2014-2017
Production and Sales of Blood Products of Shenzhen Weiguang Biological Products, 2016-2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2017
Financial Data of Plasma Collection Stations of Shenzhen Weiguang Biological Products, 2018H1
Lot Release Volume of Blood Products of Shenzhen Weiguang Biological Products, 2016-2018
Revenue and Net Income of Beijing Bohui Innovation Technology, 2014-2018
Revenue Breakdown of Beijing Bohui Innovation Technology by Product, 2014-2018
Revenue Structure of Beijing Bohui Innovation Technology by Product, 2014-2018
Gross Margin of Beijing Bohui Innovation Technology by Product, 2014-2018
R&D Costs and % of Total Revenue of Beijing Bohui Innovation Technology, 2014-2018
Progress of Major Blood Product R&D Projects of Beijing Bohui Innovation Technology, 2018H1
Financials of Beijing Bohui Innovation Technology, 2017-2018
Lot Release Volume of Blood Products of Hebei Da’an Pharmaceutical, 2016-2018
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2018
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2017
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2018
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Jan. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2018
Plasma Collection Stations of Green Cross China as of Jan. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2018
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
Market Size of Blood Products in China, 2018-2025E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2018
Plasma Collection Volume and YoY Change in China, 2018-2025E
R&D Investment of Major Chinese Blood Product Enterprises, 2013-2018

Why http://www.chinamarketresearchreports.com
China Blood Product Industry Report, 2019-2025
Published By :Research In China
Price
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy